Navigation Links
ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide
Date:7/29/2008

FREDERICK, Md., July 29 /PRNewswire/ -- ImQuest BioSciences announced today the successful acquisition of funding from the National Institute of Allergy and Infectious Disease (NIAID/NIH) to support the development of pyrimidinedione inhibitors as topical microbicides to prevent the sexual transmission of HIV. The two year Small Business Innovative Research (SBIR) grant provides funding for the continued development of the dual-acting pyrimidinedione molecules which effectively inhibit two critical steps in the HIV replication pathway important for a microbicide. The research to be performed will enable ImQuest scientist's to comparatively evaluate their most potent lead preventative agents and define the most potent microbicide candidate for advanced preclinical and clinical development.

ImQuest's Executive Vice President and Chief Scientific Officer, Dr. Robert W. Buckheit, Jr. is the Principal Investigator of the project and leads ImQuest's efforts to develop microbicide and therapeutic products for treatment and prevention of HIV infection. "Women now account for over 50% of the cases of individuals living with AIDS and the successful development of a microbicide is essential for providing them with an effective means to protect themselves from infection," explained Dr. Buckheit. "In the absence of an effective vaccine, topical microbicides represent the best means to prevent new HIV infections throughout the world."

As a component of the grant, ImQuest scientists will work in collaboration with Dr. Patrick Kiser of The University of Utah to develop an optimal formulated gel product which can be used by women to prevent the sexual transmission of HIV. ImQuest plans to file an IND to initiate human clinical microbicide trials with their lead microbicide candidate in 2009.

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in early stage drug development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective therapeutic and microbicide development services to the biotechnology and pharmaceutical industry.

For further information regarding this press release please contact:

Robert W. Buckheit, Jr., Ph.D.

Executive Vice President and Chief Scientific Officer

ImQuest Life Sciences, Inc.

301-696-0274

rbuckheit@imquest.com


'/>"/>
SOURCE ImQuest BioSciences
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India
2. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
3. Polyphenon Pharma Receives Orphan Drug Designation for Its Botanical Drug, Polyphenon E, for the Treatment of CLL
4. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
5. Cynosure Receives CE Mark for Smartlipo MPX(TM) Workstation
6. SyntheMed Receives Canadian Approval for REPEL-CV(R)
7. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
8. Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial
9. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
10. Pharmasset Receives Notice of Allowance
11. First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... -- Research and Markets has announced the ... Market Outlook 2020" report to their offering. ... technology has improved significantly in past years due to ... coming years. Many cancer drugs have been developed by ... also expected to be developed with its help. They ...
(Date:5/3/2016)... COLOGNE, Germany , May 3, 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to ... http://photos.prnewswire.com/prnh/20160503/362920    Photo - http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
(Date:5/3/2016)... Ariz. , May 3, 2016  As a ... twice contracted rheumatic fever, which damaged his heart. He ... But by June 2013, Shepherd,s heart was giving ... from death. On June 20, 2013, the ... Total Artificial Heart (TAH-t). Like a heart transplant, the ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... Registration is now open for the 31st annual ... at the Hatch Memorial Shell on the Esplanade. The event regularly draws thousands of participants, ... is a competitive, timed event fully sanctioned by the USA Track & Field Association. ...
(Date:5/3/2016)... ... ... Elizabeth Murray has always loved walking one to two miles a day. ... and one on her arm. But she got to the point where she could ... , The valves of the heart wouldn’t close properly resulting in mitral regurgitation, where ...
(Date:5/3/2016)... ... 03, 2016 , ... Empyrean Benefit Solutions, Inc., the Hi-Touch ... center in La Vergne, Tennessee, near Nashville. The new center will complement Empyrean’s ... client services. , “Our Nashville-area center allows us to achieve several goals,” said ...
(Date:5/3/2016)... , ... May 03, 2016 , ... Ogawa World USA ... its user friendly Samsung tablet and exclusive Smart Application. The Smart 3D combines the ... each massage with a customized user profile and specialized massage program, each user has ...
(Date:5/3/2016)... ... May 03, 2016 , ... Dr. Poneh Ghasri, cosmetic dentist in West ... new and existing patients. Cosmetic dentistry allows patients to improve the aesthetics of their ... with some minor or more serious cosmetic flaws. These specials allow patients to achieve ...
Breaking Medicine News(10 mins):